The JAK2 V617F mouse model is the most widely used preclinical system for dissecting the molecular pathogenesis of BCR-ABL-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This article provides a comprehensive technical overview of JAK2 V617F mouse pathogenesis research experiments, covering experimental design, sample types, testing items, analytical methods, and downstream applications in drug development and translational medicine.
Technical Overview
The JAK2 V617F mutation is an acquired somatic point mutation located in exon 14 of the Janus kinase 2 (JAK2) gene, characterized by a G-to-T substitution at nucleotide 1849 that converts valine to phenylalanine at codon 617. This mutation abrogates the autoinhibitory function of the JH2 pseudokinase domain, resulting in constitutive activation of JAK2 tyrosine kinase and persistent downstream signaling through the JAK-STAT, PI3K-AKT, and MAPK-ERK pathways. The mutation is detected in approximately 95% of polycythemia vera patients and 50-60% of patients with essential thrombocythemia or primary myelofibrosis, making it a central driver lesion in myeloproliferative neoplasms.
JAK2 V617F mouse pathogenesis research experiments utilize genetically engineered mouse models, including knock-in models (in which the mutation is inserted into the endogenous Jak2 locus) and transgenic models (in which human JAK2 V617F is expressed under hematopoietic promoters such as Vav1 or H-2Kb). These mice faithfully recapitulate the human disease phenotype, exhibiting polycythemia, leukocytosis, thrombocytosis, splenomegaly, extramedullary hematopoiesis, and progression toward myelofibrosis. Systematic phenotyping and molecular analysis of these models enable researchers to define mutation-driven mechanisms of malignant transformation, evaluate clonal evolution, and quantify therapeutic responses to JAK inhibitors such as ruxolitinib and fedratinib.
Testing Samples
Peripheral Blood
Peripheral blood is collected via tail vein, submandibular, or retro-orbital bleeding at serial time points. It is used for complete blood counts, flow cytometric immunophenotyping, plasma cytokine quantification, and circulating mutant allele burden measurement. Serial blood sampling allows longitudinal monitoring of disease initiation, progression, and treatment response within the same animal.
Bone Marrow
Bone marrow is harvested from femurs and tibias by flushing or crushing protocols. It serves as the primary source for hematopoietic stem and progenitor cell (HSPC) analysis, colony-forming unit (CFU) assays, genotyping, single-cell sequencing, and signal transduction studies. Lineage-negative Sca-1-positive c-Kit-positive (LSK) cells and myeloid progenitor subsets are typically enriched by magnetic or fluorescence-activated sorting.
Spleen and Liver
Spleen and liver tissues are collected at necropsy for weight measurement, histopathology, immunohistochemistry, and flow cytometric analysis of extramedullary hematopoiesis. Splenomegaly is a hallmark disease readout, and reticulin or Masson trichrome staining of these organs quantifies fibrosis burden, which correlates with myelofibrosis progression.
Genomic DNA, RNA, and Protein Extracts
Purified nucleic acids and protein lysates are prepared from sorted hematopoietic populations for allele-specific PCR, quantitative RT-PCR, RNA sequencing, Western blotting of phosphorylated signaling intermediates, and immunoprecipitation assays targeting STAT5, STAT3, and ERK activation states.
Testing Items
Comprehensive pathogenesis studies in JAK2 V617F mice typically include the following testing categories:
- Mutant allele genotyping and allele burden quantification in hematopoietic tissues
- Complete blood count parameters, including red blood cells, hemoglobin, hematocrit, white blood cells, neutrophils, and platelets
- Hematopoietic stem and progenitor cell frequency and differentiation skewing by flow cytometry
- Erythropoietin-independent and hypersensitive colony formation assays (BFU-E and CFU-GM)
- STAT5, STAT3, and ERK phosphorylation levels as pharmacodynamic biomarkers
- Plasma cytokine and inflammatory mediator profiling, including IL-6, TNF-alpha, and IL-1beta
- Splenic and hepatic histopathology with fibrosis grading
- Survival analysis and disease progression scoring
- Clonal evolution assessment through serial transplantation assays
- Thrombosis risk evaluation and vascular complication monitoring
Testing Methods
Genotyping and Allele Burden Quantification
Allele-specific PCR and Sanger sequencing are used for initial confirmation of the JAK2 V617F genotype. Quantitative real-time PCR with mutation-specific hydrolysis probes or droplet digital PCR provides sensitive quantification of mutant allele fraction, with detection limits below 0.1%. Next-generation sequencing panels may be applied to detect cooperating mutations in genes such as TET2, ASXL1, and DNMT3A during clonal evolution studies.
Hematological Analysis
Automated hematology analyzers measure complete blood counts using EDTA-anticoagulated peripheral blood. Key diagnostic readouts include elevated hematocrit and hemoglobin confirming polycythemia, leukocytosis with neutrophilia, and thrombocytosis. Blood smear microscopy is performed for morphological validation and identification of circulating nucleated red blood cells and teardrop cells.
Flow Cytometry
Multiparameter flow cytometry quantifies lineage composition and progenitor compartments in bone marrow and spleen. Standard panels identify LSK stem cells, common myeloid progenitors, granulocyte-macrophage progenitors, megakaryocyte-erythroid progenitors, and mature lineage markers including Gr-1, Mac-1, Ter119, CD41, and B220. Phospho-flow cytometry measures intracellular pSTAT5 levels at the single-cell level following cytokine stimulation.
Histopathology and Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of spleen, liver, and bone marrow are stained with hematoxylin and eosin for architecture evaluation. Reticulin silver staining and Masson trichrome staining grade fibrosis severity on a standardized 0-3 scale. Immunohistochemical markers such as CD41 and CD61 highlight megakaryocyte expansion and clustering, a characteristic feature of myeloproliferative disease.
Molecular and Biochemical Assays
Western blotting and ELISA quantify total and phosphorylated JAK2, STAT5, STAT3, and ERK proteins. Quantitative RT-PCR measures transcriptional output of JAK-STAT target genes. RNA sequencing and single-cell transcriptomics provide unbiased profiling of deregulated pathways, while chromatin immunoprecipitation assays define STAT5 occupancy at target promoters.
Functional Assays
Colony-forming assays culture bone marrow cells in methylcellulose media with or without erythropoietin. Erythropoietin-independent BFU-E growth is a pathognomonic functional hallmark of JAK2 V617F-driven disease. Competitive and serial transplantation assays assess disease-initiating capacity and clonal fitness of mutant stem cells.
Applications
JAK2 V617F mouse pathogenesis experiments support a broad range of translational and basic research objectives:
- Preclinical efficacy testing of JAK inhibitors, HSP90 inhibitors, PI3K inhibitors, and combination therapeutic regimens
- Pharmacodynamic biomarker validation using pSTAT5 suppression as a target engagement readout
- Mechanistic dissection of myelofibrosis initiation and extramedullary hematopoiesis
- Inflammatory niche studies linking cytokine dysregulation to disease progression and symptom burden
- Thrombosis and vascular biology research relevant to MPN-associated mortality
- Clonal evolution and mutation-order studies investigating cooperating genetic lesions
- Comparative allele burden studies distinguishing homozygous from heterozygous disease phenotypes
- Immune dysregulation and inflammation-driven clonal expansion research
- Identification of predictive biomarkers of therapeutic response and resistance
- Regulatory-enabling IND studies supporting first-in-human clinical trials
FAQ
What phenotypes do JAK2 V617F mice display?
JAK2 V617F mice develop a fully penetrant myeloproliferative phenotype characterized by elevated hematocrit, leukocytosis, thrombocytosis, marked splenomegaly, extramedullary hematopoiesis in the spleen and liver, and progressive bone marrow fibrosis. Knock-in models expressing the mutation at endogenous levels typically develop disease within 4 to 12 weeks of age depending on the promoter and genetic strategy used.
How is mutant allele burden measured and why is it important?
Allele burden is quantified by qPCR or droplet digital PCR using mutant-specific probes on genomic DNA from blood or sorted hematopoietic cells. It serves as a quantitative disease biomarker that correlates with phenotype severity, fibrosis risk, and response to therapy, making it essential for monitoring clonal dynamics during intervention studies.
Why are erythropoietin-independent colony assays performed?
Constitutive JAK2 signaling renders erythroid progenitors hypersensitive or fully independent of erythropoietin. Growth of BFU-E colonies in the absence of erythropoietin is a functional signature of the mutation and provides a cell-autonomous readout of transformation severity and drug sensitivity ex vivo.
Which model should be chosen for drug evaluation studies?
Knock-in mice expressing JAK2 V617F from the endogenous Jak2 locus offer physiologic expression levels and are preferred for pharmacology studies. Transgenic models driven by Vav1 or H-2Kb promoters produce robust, uniform disease with faster onset, which is advantageous for rapid therapeutic screening. Model selection should be aligned with the therapeutic question, timeline, and required endpoints.
How long does a typical pathogenesis study run?
A standard disease characterization study runs 8 to 16 weeks from dosing or observation start to necropsy, with serial blood sampling every 2 to 4 weeks. Long-term progression studies evaluating myelofibrosis, clonal evolution, or survival may extend to 24 weeks or longer, depending on the model aggressiveness and study objectives.
What are key considerations for experimental design and reproducibility?
Studies should include age- and sex-matched wild-type controls, littermate controls where possible, adequate sample sizes powered for primary endpoints, randomization and blinded outcome assessment, and pre-specified gating strategies for flow cytometry. Standardized housing conditions and validated genotyping assays are critical because phenotype penetrance can vary with genetic background and microbiological status.